On March 11, 2025, Xilio Therapeutics entered into a Sales Agreement allowing it to sell up to $50 million of its common stock through Leerink Partners LLC, with the agent receiving 3% of the gross proceeds. The sales will occur at market prices on the Nasdaq Global Select Market, but there is no guarantee of sales or specific amounts.